Leadoptik has entered a research partnership with Stanford Medicine, focusing on AI-enhanced real-time optical imaging usage in lung cancer biopsy.
This collaboration is set to focus on assessing the way high-resolution imaging can enhance the evaluation of lesions and biopsy precision while aiding in the development of smart tools to assist in clinical decision-making.
Go deeper with GlobalData
With the integration of real-time optical imaging and biopsy workflows, the partnership seeks to offer physicians an understanding of tissue microstructure.
The Interventional Pulmonology Program of Stanford Medicine will assess the technology’s potential in lung biopsy. It is aimed at enhancing diagnostic and therapeutic results in lung cancer and other pulmonary conditions.
It will explore how an AI-powered image interpretation joined with high-resolution visualisations could “refine” the gathering of samples and enhance patient outcomes.
The goal of the partnership is to advance diagnostic accuracy with the analysis of optical imaging data in real-world clinical settings.
This joint effort by the two entities seeks to address the difficulties in diagnosing peripheral lung nodules, which can result in “inconclusive biopsies” and delayed treatments.
Leadoptik CEO Reza Khorasaninejad said: “This partnership with Stanford marks an important step in further validating our unique real-time imaging and exploring how advanced image analysis can further support physicians.
“By combining cutting-edge imaging with emerging smart tools, we aim to improve the precision of lung biopsy procedures and enable more confident clinical decision-making.”
The imaging data from this collaboration will be instrumental in refining advanced analytics and promoting the clinical adoption of intelligent imaging solutions.
Leadoptik integrates “high-resolution visualisation” with analytics through its Last Inch Assessment (LIA) system, which aims to support decision-making in interventional pulmonology.
